Russia's leading drugmaker Pharmstandard may speed expansion this year

9 April 2018
mergers-acquisitions-big

Russian millionaire Viktor Kharitonin has consolidated the 100% stake in Pharmstandard, one of Russia’s largest drugmakers and one of the largest suppliers of drugs for state purchases, according to the company, reports The Pharma Letter’s local correspondent.

A long-time partner of Kharitonin, Yegor Kulkov resigned from the list of shareholders of the company through the sale of its stake to Mr Kharitonin. The reasons for the decision are not disclosed. The value of the 30% stake, owned by Mr Kulkov in Pharmstandard, is reportedly estimated at 16 billion roubles ($275 million).

Russian pharmaceutical business analysts believe Mr Kulkov’s decision to sell his stake in Pharmstandard may be related with the latest reports of the weakening positions of Pharmstandard in the segment of public procurements in Russia and the loss of administrative resources.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical